• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.

作者信息

Opingari Erika, Verma Subodh, Connelly Kim A, Mazer Cyril David, Teoh Hwee, Quan Adrian, Zuo Fei, Pan Yi, Bhatt Deepak L, Zinman Bernard, Leiter Lawrence A, Yan Andrew T, Cherney David Z I, Gilbert Richard E

机构信息

Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.

Institute of Medical Science, University of Toronto, Toronto, ON, Canada.

出版信息

Nephrol Dial Transplant. 2020 May 1;35(5):895-897. doi: 10.1093/ndt/gfz294.

DOI:10.1093/ndt/gfz294
PMID:32159783
Abstract
摘要

相似文献

1
The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.恩格列净对肾损伤分子-1的影响：恩格列净对2型糖尿病患者心脏结构、功能及循环生物标志物影响的CardioLink-6试验的亚分析
Nephrol Dial Transplant. 2020 May 1;35(5):895-897. doi: 10.1093/ndt/gfz294.
2
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.恩格列净与 2 型糖尿病、已确诊心血管疾病和慢性肾脏病患者的临床结局。
Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.
3
Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study.恩格列净治疗对 2 型糖尿病患者心功能和结构的影响：一项心脏磁共振研究。
Intern Med J. 2019 Aug;49(8):1006-1010. doi: 10.1111/imj.14260.
4
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
5
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.恩格列净通过 2 型糖尿病小鼠的 sGC-cGMP-PKG 通路预防心肌病。
Clin Sci (Lond). 2019 Aug 2;133(15):1705-1720. doi: 10.1042/CS20190585. Print 2019 Aug 15.
6
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.恩格列净如何改善 2 型糖尿病患者的动脉僵硬度？临床试验的亚组分析。
Cardiovasc Diabetol. 2019 Mar 29;18(1):44. doi: 10.1186/s12933-019-0839-8.
7
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.恩格列净与 2 型糖尿病患者的肾功能下降：来自 EMPA-REG OUTCOME 试验的斜率分析。
J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.
8
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.恩格列净改善伴或不伴心力衰竭患者的肾脏结局。
Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.
9
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.一项评估恩格列净对内皮功能影响的多中心安慰剂对照双盲随机试验的原理与设计：EMBLEM试验
Cardiovasc Diabetol. 2017 Apr 12;16(1):48. doi: 10.1186/s12933-017-0532-8.
10
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.恩格列净联合二甲双胍治疗改善 1 型糖尿病患者的动脉功能。
Cardiovasc Diabetol. 2018 Dec 3;17(1):153. doi: 10.1186/s12933-018-0797-6.

引用本文的文献

1
Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者心血管风险评分、代谢参数及实验室指标的影响
Life (Basel). 2025 Apr 29;15(5):722. doi: 10.3390/life15050722.
2
Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial.恩格列净与利格列汀单药及联合治疗和格列齐特相比，对超重2型糖尿病患者空腹及餐后肾脏血流动力学的影响（RACELINES）：一项随机、双盲试验
Diabetes Obes Metab. 2025 Jul;27(7):3943-3956. doi: 10.1111/dom.16431. Epub 2025 May 6.
3
Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal Doppler ultrasonography.
钠-葡萄糖协同转运蛋白2抑制剂对肾内多普勒超声检查中肾静脉淤血参数的影响。
Clin Kidney J. 2024 Aug 14;17(9):sfae234. doi: 10.1093/ckj/sfae234. eCollection 2024 Sep.
4
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD).肥胖与慢性肾脏病（CKD）的心脏代谢合并症及并发症
J Clin Transl Endocrinol. 2024 Apr 2;36:100341. doi: 10.1016/j.jcte.2024.100341. eCollection 2024 Jun.
5
Genetic and clinical characterization of familial renal glucosuria.家族性肾性糖尿的遗传学与临床特征
Clin Kidney J. 2023 Oct 17;17(2):sfad265. doi: 10.1093/ckj/sfad265. eCollection 2024 Feb.
6
Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.比较 2 型糖尿病和心力衰竭患者中不同 SGLT2 抑制剂的心血管获益：一项随机对照试验的系统评价和网络荟萃分析。
Front Endocrinol (Lausanne). 2023 Dec 20;14:1216160. doi: 10.3389/fendo.2023.1216160. eCollection 2023.
7
Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.SGLT2 抑制剂对肾小管钠、水和氯稳态的影响及其影响心力衰竭结局的作用的批判性分析。
Circulation. 2023 Jul 25;148(4):354-372. doi: 10.1161/CIRCULATIONAHA.123.064346. Epub 2023 Jul 24.
8
Diabetic Proteinuria Revisited: Updated Physiologic Perspectives.糖尿病性蛋白尿再探：更新的生理观点。
Cells. 2022 Sep 18;11(18):2917. doi: 10.3390/cells11182917.
9
Biomarkers of Kidney Tubule Disease and Risk of End-Stage Kidney Disease in Persons With Diabetes and CKD.糖尿病和慢性肾脏病患者肾小管疾病的生物标志物与终末期肾病风险
Kidney Int Rep. 2022 Apr 5;7(7):1514-1523. doi: 10.1016/j.ekir.2022.03.033. eCollection 2022 Jul.
10
SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.SGLT2 抑制剂在伴有糖尿病肾病的 1 型糖尿病中的应用：潜在的心肾获益可能超过可预防的糖尿病酮症酸中毒风险。
Curr Diab Rep. 2022 Jul;22(7):317-332. doi: 10.1007/s11892-022-01471-2. Epub 2022 May 28.